Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.04T
Market cap1.04T
Price-Earnings ratio
39.85
Price-Earnings ratio39.85
Dividend yield
0.58%
Dividend yield0.58%
Average volume
3.03M
Average volume3.03M
High today
$1,134.74
High today$1,134.74
Low today
$1,105.31
Low today$1,105.31
Open price
$1,130.00
Open price$1,130.00
Volume
902.88K
Volume902.88K
52 Week high
$1,182.73
52 Week high$1,182.73
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.04T, Eli Lilly(LLY) trades at $1,108.93. The stock has a price-to-earnings ratio of 39.85 and currently yields dividends of 0.58%.

On 2026-06-24, Eli Lilly(LLY) stock moved within a range of $1,105.31 to $1,134.74. With shares now at $1,108.93, the stock is trading +0.3% above its intraday low and -2.3% below the session's peak.

Trading activity shows a volume of 902.88K, compared to an average daily volume of 3.03M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

LLY News

Benzinga 37m
Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact

The partnership expands the relationship between the two companies as they seek to advance novel drug candidates with global potential by combining their respec...

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact
TipRanks 1h
Controversy Erupts Over Report Trump Has Early Access to Eli Lilly Weight-Loss Drug

A controversy has erupted following a media report that U.S. President Donald Trump has been granted early access to Eli Lilly’s (LLY) newest weight-loss drug b...

TipRanks 3h
Centessa Pharmaceuticals Completes Acquisition by Eli Lilly Subsidiary

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

Simply Wall St 3h
Eli Lilly Signs Abbisko Deal To Add New Drug Targets

Eli Lilly (NYSE:LLY) has entered a new multi-target research and license agreement with Abbisko Therapeutics. The partnership focuses on early-stage discovery...

Eli Lilly Signs Abbisko Deal To Add New Drug Targets
Benzinga 5h
White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President'

White House has denied reports that President Donald Trump was given access to an experimental weight-loss drug, retatrutide, under the FDA’s “compassionate use...

White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President'
TipRanks 6h
Eli Lilly uses cash pile to fund untested drug development strategies, FT says

Eli Lilly (LLY) will be using its cash pile to fund untested drug development strategies in preparation for the expiration of patents on its weight-loss drugs,...

Simply Wall St 8h
How Investors May Respond To Illumina Adding Eli Lilly R&D Chief To Its Board

Illumina, Inc. has expanded its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Office...

How Investors May Respond To Illumina Adding Eli Lilly R&D Chief To Its Board
TipRanks 20h
Eli Lilly to Launch Weight-Loss Pill in Europe Next Year

Eli Lilly (LLY) has announced plans to introduce its weight-loss pill in Europe and the United Kingdom (U.K.) early next year (2027). Unlock powerful investing...

Benzinga 22h
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle

Sangamo Therapeutics Inc. (NASDAQ:SGMO) filed for Chapter 11 bankruptcy protection on Tuesday, as the gene therapy company seeks to sell its assets through a co...

Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
TipRanks 1d
Eli Lilly Opens Data Center to Smaller Biotech Firms as It Chases Drug Discoveries

Pharmaceutical giant Eli Lilly (LLY) is undertaking an innovative new strategy that will see it partner with scientists on new drug developments. Unlock powerf...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.